Yuki Noguchi
Yuki Noguchi is a correspondent on the Science Desk based out of NPR's headquarters in Washington, D.C. She started covering consumer health in the midst of the pandemic, reporting on everything from vaccination and racial inequities in access to health, to cancer care, obesity and mental health.
Since joining NPR in 2008, Noguchi has also covered a range of business and economic news, with a special focus on the workplace — anything that affects how and why we work. In recent years, she has covered the rise of the contract workforce, the #MeToo movement, the Great Recession and the subprime housing crisis. In 2011, she covered the earthquake and tsunami in her parents' native Japan. Her coverage of the impact of opioids on workers and their families won a 2019 Gracie Award and received First Place and Best In Show in the radio category from the National Headliner Awards. She also loves featuring offbeat topics, and has eaten insects in service of journalism.
Noguchi started her career as a reporter, then an editor, for The Washington Post.
Noguchi grew up in St. Louis, inflicts her cooking on her two boys and has a degree in history from Yale.
-
A majority of people who start the obesity and diabetes medicines known as GLP-1s also quit them, and plan to restart again. Research hasn't yet shown the health impacts of cycling on and off the drugs. -
Big food companies are starting to market to people on the powerful new obesity meds with labels that say "GLP-1 Friendly." Nutritionists help us decode that message. -
The anti-parasitic drug became a household name during the COVID-19 pandemic, and it is now being embraced as an alternative treatment for cancer. It is as politically polarizing as ever. -
Easier than a blood test, saliva tests have the potential to detect cavities, infections and even cancer. But a lack of insurance coverage and other obstacles stand in the way of wider use. -
Drugs like Zepbound and Wegovy are intended for people who are overweight. Some patients are using them after bariatric surgery to keep pounds from creeping back. Others may just want to lose a few pounds. -
Doctors, patients and researchers are at the very beginning of understanding how the new class of obesity drugs interact with eating disorders. -
As doctors learn why GLP-1s don't work for about 50% of people, they are also learning more about the complex drivers of obesity. They foresee a future of personalized obesity medicine similar to the way cancer is treated now. -
Ivermectin's reputation keeps growing as a kind of cure-all, even for cancer — despite evidence it doesn't work.
-
GLP-1 weight loss drugs have transformed obesity treatment, but not everyone loses lots of weight. Researchers say figuring out why is the key to the future of this treatment method.
-
Fourteen companies in total have now reached what the administration calls most-favored-nation pricing deals.
